title: Interventions in diabetic patients after myocardial infarction.
abstract: Occurrence of a first acute myocardial infarction (AMI) is associated with further increase in risk of cardiovascular events. This risk is further increase is disproportionate in diabetics, who suffer from very high mortality short and long term after AMI. Factors responsible for the increased risk are only partially understood. Additional, properly designed, prospective epidemiological studies are needed for a better understanding of complicated diabetic macrovascular disease after the occurrence of the first event. These studies are also needed for designing interventional trials that target factors that carry the highest risk of new events. Published studies provide some insight into the issue of efficacy of blood pressure, cholesterol and blood glucose lowering strategies in the diabetic population. It remains unclear how important is the control of triglyceride concentration or other risk factors during various stages of recovery after AMI. The main reason is the lack of clinical trials. Evidence-based approach to patients with diabetes and AMI indicates the importance of tight control of cholesterol, blood pressure and blood glucose concentration. Although other risk factors have not been extensively studied, it is reasonable to assume that other major risk factors, such as hypertriglyceridemia, should be targeted as well. In the meantime, more data need to be collected from prospective epidemiological and interventional protocols, if better control over the cardiovascular risk in this high-risk population is to be achieved.
authors.affiliation: Eli Lilly Regional Medical Center, Barichgasse 40-42, A-1030, Vienna, Austria.
authors.forename: Z
authors.initials: Z
authors.lastname: Milicevic
authors.forename: I
authors.initials: I
authors.lastname: Raz
mesh_terms: D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D001786:Blood Glucose / Q000378:metabolism; D003925:Diabetic Angiopathies / Q000188:drug therapy*; D018450:Disease Progression; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D009203:Myocardial Infarction / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D014280:Triglycerides / Q000097:blood
chemical_list: D000924:Anticholesteremic Agents; D001786:Blood Glucose; D000960:Hypolipidemic Agents; D014280:Triglycerides